Harmony Biosciences Reports Officer/Director Changes & Compensation

Ticker: HRMY · Form: 8-K · Filed: 2025-03-24T00:00:00.000Z

Sentiment: neutral

Topics: management-change, officer-appointment, director-election, compensation

Related Tickers: HRMY

TL;DR

Harmony Bio just filed an 8-K: new execs, director changes, and comp details. Watch for strategy shifts.

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on March 24, 2025, reporting events as of March 20, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes information on other events and financial statements/exhibits.

Why It Matters

Changes in key leadership and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directors and officers, especially if accompanied by new compensatory arrangements, can indicate underlying strategic shifts or governance issues that may affect the company's future performance.

Key Players & Entities

FAQ

What specific roles have seen departures or appointments?

The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the exact roles in the provided text.

Are there any details on new compensatory arrangements?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not provided in the excerpt.

What is the primary reason for this 8-K filing?

The primary reasons for this 8-K filing are related to changes in the company's board of directors and executive officers, including their appointments, departures, and associated compensation.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on March 20, 2025.

What is Harmony Biosciences Holdings, Inc.'s principal executive office address?

Harmony Biosciences Holdings, Inc.'s principal executive office is located at 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462.

From the Filing

0001558370-25-003502.txt : 20250324 0001558370-25-003502.hdr.sgml : 20250324 20250324081512 ACCESSION NUMBER: 0001558370-25-003502 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250320 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250324 DATE AS OF CHANGE: 20250324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 25762312 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20250320x8k.htm 8-K 0001802665 false 0001802665 2025-03-20 2025-03-20 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of report (Date of earliest event reported): March 20, 2025 ​ HARMONY BIOSCIENCES HOLDINGS, INC . (Exact name of registrant as specified in its charter) ​ ​ ​ ​ Delaware 001-39450 82-2279923 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) ​ 630 W. Germantown Pike , Suite 215 Plymouth Meeting , PA 19462 (Address of principal executive offices) (Zip Code) ( 484 ) 539-9800 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​      Trading      Name of each exchange Title of each class ​ Symbol(s) ​ on which registered Common Stock, $0.00001 par value per share ​ HRMY ​ The Nasdaq Global Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Commercial Officer On March 24, 2025, Harmony Biosciences Holdings, Inc. (the “Company”) announced that Jeffrey Dierks will be departing from the Company as its Chief Commercial Officer, effective as of March 31, 2025 (

View on Read The Filing